Cervavac as three dose regimen
Phase 3
Cervavac as three dose regimen is one of 8 therapeutic programs targeting Human Papilloma Virus Infection. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
9 competitors in Human Papilloma Virus Infection
#DrugCompanyPhaseTrials
1Aldara
BBausch Health Americas, Inc.
Approved
Intron a
Merck & Co.Phase 2
Zarnestra
KKura Oncology, Inc.
Phase 2
Keytruda
Merck & Co.Phase 1
Balstilimab
AAgenus Inc.
Phase 2
Proleukin
IIovance Biotherapeutics, Inc.
Phase 1
Cervavac as three dose regimen
SSerum Institute of India Pvt. Ltd.
Phase 3
Intron a
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]